At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 31 enrolled
Drug / intervention
QVA149 +1 moredrug
Likely dose
QVA149 50 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Two-period Crossover Study to Assess the Effect of Inhaled QVA149 on Global and Regional Lung Function and Gas Exchange in Patients With Moderate to Severe COPD
In Brief
A Phase 4 clinical trial evaluating QVA149 and Placebo for Chronic Obstructive Pulmonary Disease. Completed, enrolled 31 participants across 3 sites.
Detailed Summary
The purpose of this study was to assess global ventilated lung volume in moderate to severe COPD patients using MRI lung imaging after treatment with QVA149 compared to placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 2015
Enrollment StartJun 2016
Primary CompletionSep 2017
TodayJul 2026
First PostedDec 18, 2015
Enrollment StartJun 3, 2016
Primary CompletionSep 26, 2017
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 10.5 years ago
Interventions
QVA149drug
QVA149 110/50 μg o.d. capsules for inhalation, supplied in blisters via the Concept 1 inhalation device, a single dose dry powder inhaler.
Placebodrug
Matching placebo